1Gregoire JP, MacNeil P, Skilton K, et al. Inter-provincial variation in government drug formularies[ J]. Can J Public Health, 2001, 92(4) : 307-312
2Bielory L, USP Model Guidelines Expert Committee. United States pharmacopeia development of the Medicare model formulary guidelines[J]. Am J Geriatr Cardiol, 2005, 14(6) : 301-307
3Fijin R, Lenderink AW, Eqberts AC, et al. Assessment of indicators for hospi- tal drug formulary non-adherence[ J]. Eur J Clin Pharmacol, 2001, 57(9) : 677~584
4Fallik B. The Academy of Managed Care Pharmacys concepts in managed care pharmacy prior authorization and the formulary exception process[Jl. JManag Care Pharm, 2005, 11(4) : 358-361
5Lehunann DF, Guharoy, Page N, et al. Formulary management as a tool to improve medication use and gain physician support[J]. Am J Health Syst Pharm, 2007, 64(5) : 464-466
6Smetana GW, Davis RB, Phillips RS. Factors that influence patient response to requests to change to a unified restrictive formulary [ J ]. J Gen Intern Med, 2004, 19(12): 1212-1219
7Olson BM. Approaches to pharmacy benefit management and the impact of consumer cost sharing [J]. Clin Ther, 2003, 25( 1 ) : 250-272
8Shalansky SJ, Virk R, Ackman M, et al. Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process [J]. Can J Cardiol, 2003, 19(2) : 173-179
9Fullerton DS, Atherly DS. Formularies, therapeutics, and outcomes : new opportunities[J].Med Care, 2004, 42(4 Suppl) : 11139-44
10Simon GE, Psaty BM, Hrachoves JB, et al. Principles for evidence-based drug formulary policy[J]. J Gen Intern Med, 2005, 20(10) : 964-968
二级参考文献4
1[1]Highlights-WHO Medicines Strategy:2000-2003,Frame-work for action in essential drugs and medicines policy,Geneva,WHO 29-30 June 1999
2[12]Report of the WHO expert committee on national drug policies Geneva,WHO 19-23 June 1995,WHO/DAP 195.9
